Key facts
- Kamari Pharma’s last known valuation is $42.8M (Jun 2025).
- It has raised $48.0M; the latest was Later Stage VC ($23.0M) in Jun 2025.
- Notable investors include Arkin Capital, Wille Finance, BRM Group, Guangzhou Sino-Israel Bio-Industry Investment Fund, Pontifax Venture Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Kamari Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Kamari Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kamari Pharma
Developer of a bio-pharmaceutical platform designed to develop proprietary small-molecule inhibitors. The company's platform uses a scientific approach to treat conditions of the skin with no current treatments by targeting the root cause of serum calcium dysregulation, enabling patients to get treatment for various dermatological conditions.
- Sector
- Healthcare
- HQ
- Ness Ziona, Israel
- Founded
- 2018
- Employees
- 8
- Website
- kamaripharma.com/
- Ownership
- Privately Held (backing)
Kamari Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kamari Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kamari Pharma in its N-PORT filings yet. We sweep new filings monthly.